5358 research outputs found
Sort by
Family-related antecedents of business legality: an empirical investigation among Italian family owned SMEs
No full textWe investigate the relationship between family-related factors in family owned businesses and the level of business legality, which is a key dimension of corporate social responsibility, surprisingly neglected despite its business and social relevance. By adopting the ability and willingness perspective, and merging it with signaling theory, we consider family involvement in management and generational stage as key antecedents of legal behavior in family owned businesses. We utilize an official legality rating recently developed by the Italian Competition Authority to build a unique dataset of 161 Italian family owned SMEs. Results from a regression analysis confirm our hypotheses: business legality increases with higher levels of family involvement in management, and at later generational stages
Budget impact analysis of breast cancer screening in Italy: the role of new technologies
No full textAlthough mammography screening significantly reduces breast cancer mortality, women could present different morphological characteristics that do not allow the correct vision of their breasts and the detection of cancer, resulting in a delay of diagnosis and an increase in the risk of mortality. The present study aims at analyzing potential areas of improvement of the current screening programs and then hypothesizing alternative technologies to use within the diagnostic phase, from an economic point of view. A Budget Impact Analysis approach was implemented, considering the Italian National Healthcare Service perspective, and representing the healthcare expenditure evolution, over three years. In the Budget Impact Analysis model, two distinct phases of the screening programs were considered: (1) the screening/diagnosis phase and (2) the phase related to cancer care and treatments of patients. The results provide clinicians and policy makers with a rational method to forecast economic resources in the screening programs in a general context of limited resources. In particular, results of the Budget Impact Analysis showed that, while the introduction of the ABUS InveniaTM technology into the screening programs would lead to an increase in the screening phase expenditure, it would generate an economic advantage related to the patients treatment and care
Monocentric analysis of the effectiveness and financial consequences of the use of lenograstim versus filgrastim for mobilization of peripheral blood progenitor cells in patients with lymphoma and myeloma receiving chemotherapy and autologous stem cell transplantation
No full textPurpose: Granulocyte-colony stimulating factors (G-CSFs) are widely used to mobilize CD34+ stem cells and to support the engraftment after hematopoietic stem cell transplantation (HSCT). A budget impact analysis and an incremental cost-effectiveness study of two G-CSFs (Lenograstim and Filgrastim biosimilar), considering engraftment, number of hospitalization days and number of G-CSF vials administered were performed. Patients and Methods: Between 2009 and 2016, 248 patients undergoing autologous HSCT have been evaluated and divided into three groups (100 Leno-Leno, 93 Leno-Fil, 55 Fil-Fil) according to the type of G-CSF used for hematopoietic stem cell mobilization and hematopoietic stem cell recovery after transplant. Results: The following statistically significant differences have been observed between Leno-Leno, Leno-Fil, Fil-Fil groups: a higher number of harvested CD34+ cells (10.56 vs 8.00 vs 7.20; p=0.0003) and a lower number of G-CSF vials (8 vs 8 vs 9; p=0.00020) used for full bone marrow recovery favoring Lenograstim. No statistically significant differences were found regarding the number of G-CSF vials used for mobilization, apheresis number and CD34+ cell peak. The post-transplant hematological recovery was faster in Lenograstim group than Filgrastim group: median time to neutrophil count engraftment (> 500/mmc) was 12 vs 13 days; median time for platelets recovery (> 20.000/mmc) was 12 vs 15 days (p=0.0001). The use of Lenograstim achieved cost savings of € 566/patient over Filgrastim biosimilar, related to a decreased number of days of hospitalization (16 vs 17 days; p=0.00012), a lower overall incidence of adverse events, laboratory tests, transfusions for platelet recovery following discharge. Conclusion: In our experience, Lenograstim outperforms Filgrastim in terms of effectiveness and lower cost. This study shows a clinical superiority of Lenograstim over Filgrastim suggesting a potential cost savings favoring Lenograstim
The complexity of the intangible digital economy: an agent-based model
No full textDuring the last decades, we have witnessed a strong development of intangible digital technologies. Software, artificial intelligence and algorithms are increasingly affecting both production systems and our lives; economists have started to figure out the long-run complex economic implications of this new technological wave. In this paper, we address this question through the agent-based modelling approach. In particular, we enrich the macroeconomic model Eurace with the concept of intangible digital technology and investigate its effects both at the micro and macro level. Results show the emergence of the relevant stylized facts observed in the business domain, such as increasing returns, winner-take-most phenomena and market lock-in. At the macro level, our main finding is an increasing unemployment level, since the sizeable decrease of the employment rate in the mass-production system, provided by the higher productivity of digital assets, is usually not counterbalanced by the new jobs created in the digital sector
Analisi delle ricadute organizzative ed economiche del trattamento dei pazienti infetti da virus dell'Epatite C in Italia in relazione a differenti durate del trattamento antivirale
No full textValue based healthcare: soluzione per l'ottimizzazione in sanità
No full textSecondo alcuni, la Value Based Healthcare (VBHC) è una delle più appropriate risposte che il SSN può fornire in un periodo storico caratterizzato da finanziamento a isorisorse.According to some, Value Based Healthcare (VBHC) is one of the most appropriate answers that the NHS can provide in a historical a period characterized by financing with few resources by funding for resources
Qualitative robustness of set-valued value-at-risk
No full textRisk measures are defined as functionals of the portfolio loss distribution, thus implicitly assuming the knowledge of such a distribution. However, in practical applications, the need for estimation arises and with it the need to study the effects of mis-specification errors, as well as estimation errors on the final conclusion. In this paper we focus on the qualitative robustness of a sequence of estimators for set-valued risk measures. These properties are studied in detail for two well-known examples of set-valued risk measures: the value-at-risk and the maximum average value-at-risk. Our results illustrate, in particular, that estimation of set-valued value-at-risk can be given in terms of random sets. Moreover, we observe that historical set-valued value-at-risk, while failing to be sub-additive, leads to a more robust procedure than alternatives such as the maximum likelihood average value at-risk
